Psycholinguistics of aphasia pharmacotherapy: Asking the right questions

Aphasiology

Volumn 28, Issue 2, 2014, Pages 133-154

  Cahana Amitay, Dalia ^a   Albert, Martin L ^a   Oveis, Abigail ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aphasia; Language; Pharmacotherapy; Psycholinguistics

Indexed keywords

AMANTADINE; AMIRIDINE; ANIRACETAM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIFEMELANE; BROMOCRIPTINE; CATECHOLAMINE; CEREBROLYSIN; CHLORDIAZEPOXIDE; DEXAMPHETAMINE; DONEPEZIL; FLUVOXAMINE; GALANTAMINE; LEVODOPA; MEMANTINE; METHYLPHENIDATE; MOCLOBEMIDE; NEUROTRANSMITTER; NILVADIPINE; PIRACETAM; PLACEBO; PROPRANOLOL; VASOPRESSIN; ZOLPIDEM;

ALZHEIMER DISEASE; APHASIA; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; HUMAN; LANGUAGE ABILITY; LINGUISTICS; MOTOR PERFORMANCE; MULTIINFARCT DEMENTIA; NERVE CELL NETWORK; NEUROBIOLOGY; NEUROMODULATION; NORADRENERGIC SYSTEM; PARKINSON DISEASE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPEECH THERAPY; TREATMENT OUTCOME;

EID: 84890347151     PISSN: 02687038     EISSN: 14645041     Source Type: Journal    
DOI: 10.1080/02687038.2013.818099     Document Type: Review

References (97)

1. Aarsland, D., Larsen, J. P., Reinvang, I., & Aasland, A. M. (1994). Effects of cholinergic blockade on language in healthy young women: Implications for the cholinergic hypothesis in dementia of the Alzheimer type. Brain, 117(6), 1377-1384. doi:10.1093/brain/117.6.1377
2. Albert, M. L. (1988). Neurobiological aspects of aphasia therapy. Aphasiology, 2(3-4), 215-218. doi:10.1080/02687038808248912
3. Albert, M. L. (2000). Toward a neurochemistry of naming and anomia. In Y. Grodzinsky, L. Shapiro, & D. Swinney (Eds.), Language and the brain (pp. 157-165). San Diego, CA: Academic Press.
4. Alexander, M. P. (2006). Impairments of procedures for implementing complex language are due to disruption of frontal attention processes. Journal of the International Neuropsychological Society: JINS, 12(2), 236-247. doi:10.1017/S1355617706060309
5. Angwin, A. J., Copland, D. A., Chenery, H. J., Murdoch, B. E., & Silburn, P. A. (2006). The influence of dopamine on semantic activation in Parkinson's disease. Neuropsychology, 20, 299-306.
6. Arciniegas, D. B., Frey, K. L., Anderson, C. A., Brousseau, K. M., & Harris, S. N. (2004). Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy. Brain Injury, 18(12), 1309-1318.
7. Ashtary, F., Janghorbani, M., Chitsaz, A., Reisi, M., & Bahrami, A. (2006). A randomized, double-blind trial of bromocriptine efficacy in nonfluent aphasia after stroke. Neurology, 66(6), 914-916. doi:10.1212/01.wnl.0000203119.91762.0c
8. Barrett, A. M., & Eslinger, P. J. (2007). Amantadine for adynamic speech: Possible benefit for aphasia? American Journal of Physical Medicine and Rehabilitation, 86(8), 605-612.
9. Benton, A. L., & Hamsher, K. (1976). Multilingual aphasia examination. Iowa: University of Iowa.
10. Berthier, M.L. (1999). Transcortical aphasia. Hove: Psychology Press.
11. Berthier, M. L. (2005). Poststroke aphasia: Epidemiology, pathophysiology and treatment. Drugs & Aging, 22(2), 163-182.
12. Berthier, M. L., García-Casares, N., Walsh, S. F., Nabrozidis, A., de Mier, R. J. R., Green, C.,. Pulvermüller, F. (2011). Recovery from post-stroke aphasia: Lessons from brain imaging and implications for rehabilitation and biological treatments. Discovery Medicine, 12(65), 275-289.
13. Berthier, M. L., Green, C., Higueras, C., Fernández, I., Hinojosa, J., & Martín, M. C. (2006). A randomized, placebo-controlled study of donepezil in poststroke aphasia. Neurology, 67(9), 1687-1689. doi:10.1212/01.wnl.0000242626.69666.e2
14. Berthier, M. L., Green, C., Lara, J. P., Higueras, C., Barbancho, M. A., Dávila, G., & Pulvermüller, F. (2009). Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Annals of Neurology, 65(5), 577-585. doi:10.1002/ana.21597
15. Berthier, M. L., Hinojosa, J., Martín, M. del C., & Fernández, I. (2003). Open-label study of donepezil in chronic poststroke aphasia. Neurology, 60(7), 1218-1219. doi:10.1212/01.WNL.0000055871.82308.41
16. Berthier, M. L., Hinojosa, J., & Moreno-Torre, I. (2004). Beneficial effects of donepezil and modality-specific language therapy on chronic conduction aphasia. Neurology, 62(Suppl 5), A462.
17. Berthier, M. L., & Pulvermüller, F. (2011). Neuroscience insights improve neurorehabilitation of poststroke aphasia. Nature Reviews Neurology, 7(2), 86-97. doi:10.1038/nrneurol.2010.201
18. Beversdorf, D. Q., Narayanan, A., Hillier, A., & Hughes, J. D. (2007). Network model of decreased context utilization in autism spectrum disorder. Journal of Autism and Developmental Disorders, 37(6), 1040-1048. doi:10.1007/s10803-006-0242-7
19. Bragoni, M., Altieri, M., Di Piero, V., Padovani, A., Mostardini, C., & Lenzi, G. L. (2000). Bromocriptine and speech therapy in non-fluent chronic aphasia after stroke. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 21(1), 19-22.
20. Breitenstein, C., Wailke, S., Bushuven, S., Kamping, S., Zwitserlood, P., Ringelstein, E. B., & Knecht, S. (2004). D-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 29(9), 1704-1714. doi:10.1038/sj.npp.1300464
21. Cahana-Amitay, D., Albert, M. L., Pyun, S.-B., Westwood, A., Jenkins, T., Wolford, S., & Finley, M. (2011). Language as a stressor in aphasia. Aphasiology, 25(2), 593-614. doi:10.1080/02687038.2010.541469
22. Caplan, D. (2009). Experimental design and interpretation of functional neuroimaging studies of cognitive processes. Human Brain Mapping, 30(1), 59-77. doi:10.1002/hbm.20489
23. Chen, Y., Li, Y.-S., Wang, Z.-Y., Xu, Q., Shi, G.-W., & Lin, Y. (2010). The efficacy of donepezil for post-stroke aphasia: A pilot case control study. Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine], 49(2), 115-118.
24. Cherney, L. R., Erickson, R. K., & Small, S. L. (2010). Epidural cortical stimulation as adjunctive treatment for non-fluent aphasia: Preliminary findings. Journal of Neurology, Neurosurgery, and Psychiatry, 81(9), 1014-1021. doi:10.1136/jnnp.2009.184036
25. Cohen, L., Chaaban, B., & Habert, M. O. (2004). Transient improvement of aphasia with zolpidem. New England Journal of Medicine, 350(9), 949-950.
26. Connor, L. T., & Fucetola, R. P. (2011). Assessment of attention in people with aphasia: Challenges and recommendations. Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders, 21(2), 55-63. doi:10.1044/nnsld21.2.55
27. Corbett, F., Jefferies, E., & Lambon Ralph, M. A. (2008). The use of cueing to alleviate recurrent verbal perseverations: Evidence from transcortical sensory aphasia. Aphasiology, 22(4), 363-382. doi:10.1080/02687030701415245
28. Crosson, B., Moore, A. B., Gopinath, K., White, K. D., Wierenga, C. E., Gaiefsky, M. E.,. Gonzalez Rothi, L. J. (2005). Role of the right and left hemispheres in recovery of function during treatment of intention in aphasia. Journal of Cognitive Neuroscience, 17(3), 392-406. doi:10.1162/0898929053279487
29. Darley, F. L., Keith, R. L., & Sasanuma, S. 1977. The effect of alerting and tranquilizing drugs on upon the performance of aphasic patients. Clinical Aphasiology, 7, 91-96.
30. De Boissezon, X., Peran, P., De Boysson, C., & Démonet, J.-F. (2007). Pharmacotherapy of aphasia: Myth or reality? Brain and Language, 102(1), 114-125. doi:10.1016/j.bandl.2006.07.004
31. Floel, A., & Cohen, L. G. (2010). Recovery of function in humans: Cortical stimulation and pharmacological treatments after stroke. Neurobiology of Disease, 37(2), 243-251. doi:10.1016/j.nbd.2009.05.027
32. Gold, M., Van Dam, D., & Silliman, E. R. (2000). An open-label trial of bromocriptine in nonfluent aphasia: A qualitative analysis of word storage and retrieval. Brain and Language, 74(2), 141-156.
33. Goral, M., Clark-Cotton, M., Spiro, A., Obler, L. K., Verkuilen, J., & Albert, M. L. (2011). The contribution of set switching and working memory to sentence processing in older adults. Experimental Aging Research, 37(5), 516-538. doi:10.1080/0361073X.2011.619858
34. Gotts, S. J., Della Rocchetta, A. I., & Cipolotti, L. (2002). Mechanisms underlying perseveration in aphasia: Evidence from a single case study. Neuropsychologia, 40(12), 1930-1947. doi:10.1016/S0028-3932(02)00067-2
35. Güngör, L., Terzi, M., & Onar, M. K. (2011). Does long term use of piracetam improve speech disturbances due to ischemic cerebrovascular diseases? Brain and Language, 117(1), 23-27. doi:10.1016/j.bandl.2010.11.003
36. Gupta, S. R., & Mlcoch, A. G. (1992). Bromocriptine treatment of nonfluent aphasia. Archives of Physical Medicine and Rehabilitation, 73(4), 373-376.
37. Gupta, S. R., Mlcoch, A. G., Scolaro, C., & Moritz, T. (1995). Bromocriptine treatment of nonfluent aphasia. Neurology, 45, 2170-2173.
38. Hasselmo, M. E., Linster, C., Patil, M., Ma, D., & Cekic, M. (1997). Noradrenergic suppression of synaptic transmission may influence cortical signal-to-noise ratio. Journal of Neurophysiology, 77(6), 3326-3339.
39. Heilman, K. M., Nadeau, S. E., & Beversdorf, D. O. (2003). Creative innovation: Possible brain mechanisms. Neurocase, 9(5), 369-379. doi:10.1076/neur.9.5.369.16553
40. Heiss, W.-D., & Thiel, A. (2006). A proposed regional hierarchy in recovery of post-stroke aphasia. Brain and Language, 98(1), 118-123. doi:10.1016/j.bandl.2006.02.002
41. Hong, J. M., Shin, D. H., Lim, T. S., Lee, J. S., & Huh, K. (2012). Galantamine administration in chronic post-stroke aphasia. Journal of Neurology, Neurosurgery, and Psychiatry, 83, 675-680. doi: 10.1136/jnnp-2012-302268
42. Huber, W., Willmes, K., Poeck, K., Van Vleymen, B., & Deberdt, W. (1997). Piracetam as an adjuvant to language therapy for aphasia: A randomized double-blind placebo-controlled pilot study. Archives of Physical Medicine and Rehabilitation, 78(3), 245-250.
43. Jianu, D. C., Muresanu, D. F., Bajenaru, O., Popescu, B. O., Deme, S. M., Moessler, H.,. Ursoniu, S. (2010). Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery. Journal of Medicine and Life, 3(3), 297-307.
44. Johnson, N. A., Rademaker, A., Weintraub, S., Gitelman, D., Wienecke, C., & Mesulam, M. (2010). Pilot trial of memantine in primary progressive aphasia. Alzheimer Disease and Associated Disorders, 24(3), 308.
45. Kaplan, E. (1983). Boston naming test. Philadelphia, PA: Lea & Febiger.
46. Kertesz, A., Morlog, D., Light, M., Blair, M., Davidson, W., Jesso, S., & Brashear, R. 2008. Galantamine in frontotemporal dementia and primary progressive aphasia. Dementia and Geriatric Cognitive Disorders, 25, 178-185.
47. Kertesz, A., Sheppard, A., & MacKenzie, R. (1982). Localization in transcortical sensory aphasia. Archives of Neurology, 39(8), 475-478.
48. Kessler, J., Thiel, A., Karbe, H., & Heiss, W. D. (2000). Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke; A Journal of Cerebral Circulation, 31(9), 2112-2116.
49. Kiran, S., & Johnson, L. (2008). Semantic complexity in treatment of naming deficits in aphasia: Evidence from well-defined categories. American Journal of Speech-Language Pathology, 17(4), 389-400. doi:10.1044/1058-0360(2008/06-0085
50. Kiran, S., & Thompson, C. K. (2003). The role of semantic complexity in treatment of naming deficits: Training semantic categories in fluent aphasia by controlling exemplar typicality. Journal of Speech, Language, and Hearing Research, 46(4), 773-787. doi:10.1044/1092-4388(2003/061
51. Klein, R. B., & Albert, M. L. (2004). Can drug therapies improve language functions of individuals with aphasia? A review of the evidence. Seminars in Speech and Language, 25(2), 193-204. doi:10.1055/s-2004-825655
52. Knecht, S., Breitenstein, C., Bushuven, S., Wailke, S., Kamping, S., Flöel, A.,. Ringelstein, E. B. (2004). Levodopa: Faster and better word learning in normal humans. Annals of Neurology, 56(1), 20-26. doi:10.1002/ana.20125
53. Kurland, J. (2011). The role that attention plays in language processing. Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders, 21(2), 47-54.
54. Laska, A. C., von Arbin, M., Kahan, T., Hellblom, A., & Murray, V. (2005). Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: A randomised, double-blind, placebo-controlled study. Cerebrovascular Diseases, 19(2), 125-132.
55. Lazar, R. M., & Antoniello, D. (2008). Variability in recovery from aphasia. Current Neurology and Neuroscience Reports, 8(6), 497-502.
56. Lee, A. W., & Hillis, A. E. (2008). The pharmacological treatment of aphasia. In B. Stemmer & H. A. Whitaker (Eds.), Handbook of the neuroscience of language (pp. 407-415). London: Academic Press.
57. Leeman, B., Laganaro, M., Chetelat-Mabillard, D., & Schnider, A. (2011). Crossover trial of subacute computerized aphasia therapy for anomia with the addition of either levodopa or placebo. Neurorehabilition and Neural Repair, 25(1), 43-47.
58. Luriiâ, A. R. (1970). Traumatic aphasia: Its syndromes, psychology and treatment. The Hague: Mouton.
59. MacLennan, D. L., Nicholas, L. E., Morley, G. K., & Brookshire, R. H. (1991). The effects of bromocriptine on speech and language function in a man with transcortical aphasia. Clinical Aphasiology, 21, 145-155.
60. Martin, N., & Reilly, J. J. (2012). Introduction to special issue. Short-term memory/working memory impairments in aphasia: Data, models and their application to aphasia rehabilitation. Aphasiology, 26(3/4), 253-257.
61. McNamara, P., & Albert, M. L. (2004). Neuropharmacology of verbal perseveration. Seminars in Speech and Language, 25(4), 309-321. doi:10.1055/s-2004-837244
62. McNeil, M. R., Doyle, P. J., Spencer, K. A., Goda, A. J., Flores, D., & Small, S. L. (1997). A double-blind, placebo-controlled study of pharmacological and behavioural treatment of lexical-semantic deficits in aphasia. Aphasiology, 11(4-5), 385-400.
63. McNeil, M. R., Small, S. L., Masterson, R. J., & Fossett, T. R. D. (1995). Behavioral and pharmacological treatment of lexical-semantic deficits in a single patient with primary progressive aphasia. American Journal of Speech-Language Pathology, 4(4), 76-87.
64. Mimura, M., Albert, M. L., & McNamara, P. (1995). Toward a pharmacotherapy for aphasia. In H. Kirshner (Ed.), Handbook of neurological speech and language disorders (pp. 465-482). New York, NY: Marcel Dekker.
65. Nadeau, S. E., & Wu, S. S. (2006). CIMT as a behavioral engine in research on physiological adjuvants to neurorehabilitation: The challenge of merging animal and human research. NeuroRehabilitation, 21(2), 107-130.
66. Obler, L. K., & Albert, M. L. (1979). The action naming test (experimental edition). Boston, MA: VA Medical Center.
67. Orgogozo, J. M. (1999). Piracetam in the treatment of acute stroke. Pharmacopsychiatry, 32(Suppl. 1), 25-32.
68. Ozeren, A., Sarica, Y., Mavi, H., & Demirkiran, M. (1995). Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia. Acta Neurologica Belgica, 95(4), 235-238.
69. Pashek, G. V., & Bachman, D. L. (2003). Cognitive, linguistic, and motor speech effects of donepezil hydrochloride in a patient with stroke-related aphasia and apraxia of speech. Brain and Language, 87, 179-180.
70. Pulvermüller, F., Neininger, B., Elbert, T., Mohr, B., Rockstroh, B., Koebbel, P., & Taub, E. (2001). Constraint-induced therapy of chronic aphasia after stroke. Stroke; A Journal of Cerebral Circulation, 32(7), 1621-1626.
71. Rapp, B., Caplan, D., Edwards, S., Visch-Brink, E., & Thompson, C. K. (2013). Neuroimaging in aphasia treatment research: Issues of experimental design for relating cognitive to neural changes. NeuroImage, 73, 200-207. doi:10.1016/j.neuroimage.2012.09.007
72. Rapp, B., & Goldrick, M. (2006). Speaking words: Contributions of cognitive neuropsychological research. Cognitive Neuropsychology, 23(1), 39-73. doi:10.1080/02643290542000049
73. Raymer, A. M. (2003). Treatment of adynamia in aphasia. Frontiers in Bioscience: A Journal and Virtual Library, 8, s845-s851.
74. Raymer, A. M., Bandy, D., Adair, J. C., Schwartz, R. L., Williamson, D. J., Gonzalez Rothi, L. J., & Heilman, K. M. (2001). Effects of bromocriptine in a patient with crossed nonfluent aphasia: A case report. Archives of Physical Medicine and Rehabilitation, 82(1), 139-144. doi:10.1053/apmr.2001.18056
75. Reed, D. A., Johnson, N. A., Thompson, C., Weintraub, S., & Mesulam, M. M. (2004). A clinical trial of bromocriptine for treatment of primary progressive aphasia. Annals of Neurology, 56(5), 750. doi: 10.1002/ana.20301
76. Sabe, L., Leiguarda, R., & Starkstein, S. E. (1992). An open-label trial of bromocriptine in nonfluent aphasia. Neurology, 42, 1637-1638.
77. Sabe, L., Salvarezza, F., García Cuerva, A., Leiguarda, R., & Starkstein, S. (1995). A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia. Neurology, 45(12), 2272-2274.
78. Sarter, M., Hasselmo, M. E., Bruno, J. P., & Givens, B. (2005). Unraveling the attentional functions of cortical cholinergic inputs: Interactions between signal-driven and cognitive modulation of signal detection. Brain Research Brain Research Reviews, 48(1), 98-111. doi:10.1016/j.brainresrev.2004.08.006
79. Seniów, J., Litwin, M., Litwin, T., Leśniak, M., & Członkowska, A. (2009). New approach to the rehabilitation of post-stroke focal cognitive syndrome: Effect of levodopa combined with speech and language therapy on functional recovery from aphasia. Journal of the Neurological Sciences, 283(1-2), 214-218. doi:10.1016/j.jns.2009.02.336
80. Shisler, R. J., Baylis, G. C., & Frank, E. M. (2000). Pharmacological approaches to the treatment and prevention of aphasia. Aphasiology, 14(12), 1163-1186. doi:10.1080/02687030050205705
81. Small, S. L. (1994). Pharmacotherapy of aphasia. A critical review. Stroke, 25(6), 1282-1289. doi:10.1161/01.STR.25.6.1282
82. Small, S. L. (2000). The future of aphasia treatment. Brain and Language, 71(1), 227-232. doi:10.1006/brln.1999.2256S
83. Small, S. L., & Llano, D. A. (2009). Biological approaches to aphasia treatment. Current Neurology and Neuroscience Reports, 9(6), 443-450. doi:10.1007/s11910-009-0066-x
84. Sommer, I. E. C., Oranje, B., Ramsey, N. F., Klerk, F. A., Mandl, R. C. W., Westenberg, H. G. M., & Kahn, R. S. (2006). The influence of amphetamine on language activation: An fMRI study. Psychopharmacology, 183(4), 387-393. doi:10.1007/s00213-005-0176-3
85. Tanaka, Y., & Albert, M. L. (2001). Cholinergic therapy for fluent aphasia. Presented at the Annual Meeting of American Neurological Association, Chicago, IL.
86. Tanaka, Y., Albert, M. L., Aketa, S., Hujita, K., Noda, E., Takashima, M.,. Tanaka, M. (2004). Serotonergic therapy for fluent aphasia. Neurology, 62(7, Suppl. S5), A166.
87. Tanaka, Y., Albert, M. L., Fujita, K., Nonaka, C., & Oka, T. (2007). Beta blocker improves language output in aphasia. Neurological Medicine (Japan), 67, 277-281.
88. Tanaka, Y., Albert, M. L., Hujita, F., Nonaka, C., & Oka, T. (2006). Beta-blocker improves language output in aphasia. Presented at the Annual Meeting of the American Neurological Association, Chicago, IL.
89. Tanaka, Y., Cahana-Amitay, D., Albert, M., Fujita, K., Nonaka, C., & Miyazaki, M. (2010). Treatment of anxiety in aphasia. Procedia Social and Behavioral Sciences, 6, 252-253. doi:10.1016/j.sbspro.2010.08.061
90. Tanaka, Y., Miyazaki, M., & Albert, M. L. (1997). Effects of increased cholinergic activity on naming in aphasia. The Lancet, 350(9071), 116-117. doi:10.1016/S0140-6736(05)61820-X
91. Thompson, C. K., Den Ouden, D.-B., Bonakdarpour, B., Garibaldi, K., & Parrish, T. B. (2010). Neural plasticity and treatment-induced recovery of sentence processing in agrammatism. Neuropsychologia, 48(11), 3211-3227. doi:10.1016/j.neuropsychologia.2010.06.036
92. Thompson, C. K., & Shapiro, L. P. (2007). Complexity in treatment of syntactic deficits. American Journal of Speech-Language Pathology, 16(1), 30-42. doi:10.1044/1058-0360(2007/005
93. Thompson, C. K., Shapiro, L. P., Kiran, S., & Sobecks, J. (2003). The role of syntactic complexity in treatment of sentence deficits in agrammatic aphasia: The complexity account of treatment efficacy (CATE). Journal of Speech, Language, and Hearing Research, 46(3), 591-607.
94. Tsikunov, S. G., & Belokoskova, S. G. (2007). Psychophysiological analysis of the influence of vasopressin on speech in patients with post-stroke aphasia. The Spanish Journal of Psychology, 10(1), 178-188.
95. Walker-Batson, D., Curtis, S., Natarajan, R., Ford, J., Dronkers, N., Salmeron, E.,. Unwin, D. H. (2001). A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke, 32(9), 2093-2098. doi:10.1161/hs0901.095720
96. Walker-Batson, D., Unwin, H., Curtis, S., Allen, E., Wood, M., Smith, P.,. Greenlee, R. G. (1992). Use of amphetamine in the treatment of aphasia. Restorative Neurology and Neuroscience, 4(1), 47-50. doi:10.3233/RNN-1992-4106
97. Whiting, E., Chenery, H. J., Chalk, J., & Copland, D. A. (2007). Dexamphetamine boosts naming treatment effects in chronic aphasia. Journal of the International Neuropsychological Society: JINS, 13(6), 972-979. doi:10.1017/S1355617707071317